Blood-brain barrier dysfunction as a potential therapeutic target for neurodegenerative disorders

다국어 초록 (Multilingual Abstract)

The blood-brain barrier (BBB) is composed ofspecifi c tight junction proteins and transporters expressed onthe lining of endothelial cells of the vasculature in the brain.
The structural and functional integrity of the BBB is one ofthe most critical factors for maintaining brain homeostasisand is mainly regulated by complex interactions betweenvarious cell types, such as endothelial cells, pericytes, andastrocytes, which are shaped by their diff erential responsesto changes in microenvironments. Alterations in these cellularcomponents have been implicated in neurodegenerativedisorders. Although it has long been considered thatBBB dysfunction is a mere ramifi cation of pathologicalphenomena, emerging evidence supports its critical role inthe pathogenesis of various disorders. In epilepsy, heightenedBBB permeability has been found to be associated withincreased occurrence of spontaneous seizures. Additionally,exaggerated infl ammatory responses signifi cantly correlatewith increased BBB permeability during healthy aging. Furthermore,it has been previously reported that BBB disruptioncan be an early marker for predicting cognitive impairmentin the progression of Alzheimer’s disease. We hereinreview a potential role of the major cellular components ofthe BBB, with a focus on the contribution of BBB disruption,in neurodegenerative disease progression.

참고문헌 (Reference)

1 Olga Tornavaca, "ZO-1 controls endothelial adherens junctions, cell–cell tension, angiogenesis, and barrier formation" Rockefeller University Press 208 (208): 821-838, 2015

2 Christina M. Van Itallie, "ZO-1 Stabilizes the Tight Junction Solute Barrier through Coupling to the Perijunctional Cytoskeleton" American Society for Cell Biology (ASCB) 20 (20): 3930-3940, 2009

3 Luo WD, "Vitexin reduces epilepsy after hypoxic ischemia in the neonatal brain via inhibition of NKCC1" 15 (15): 1-15, 2018

4 Daniels BP, "Viral pathogen-associated molecular patterns regulate blood-brain barrier integrity via competing innate cytokine signals" 2014

5 Mario Merlini, "Vascular β-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAβ mice" Springer Science and Business Media LLC 122 (122): 293-311, 2011

6 Chakraborty A, "Vascular endothelial growth factor remains unchanged in cerebrospinal fl uid of patients with Alzheimer’s disease and vascular dementia" 10 (10): 1-7, 2018

7 Wilcock DM, "Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer’s disease" 159 (159): 055-1069, 2009

8 TSAOH-P NHSU, "Tumour necrosis factor-α causes an increase in blood-brain barrier permeability during sepsis" 50 (50): 812-821, 2001

9 Sabeh F, "Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP" 167 (167): 769-781, 2004

10 heaux LP, "Transcriptome profi ling reveals TGF-β signaling involvement in epileptogenesis" 29 (29): 8927-8935, 2009

11 Richard M. Ransohoff, "Three or more routes for leukocyte migration into the central nervous system" Springer Science and Business Media LLC 3 (3): 569-581, 2003

12 Fanning AS, "The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton" 273 (273): 29745-29753, 1998

13 Barbara Pijet, "The matrix metalloproteinase inhibitor marimastat inhibits seizures in a model of kainic acid-induced status epilepticus" Springer Science and Business Media LLC 10 (10): 1-12, 2020

14 Broekaart DW, "The matrix metalloproteinase inhibitor IPR-179 has antiseizure and antiepileptogenic eff ects" 2021

15 de Vries HE, "The infl uence of cytokines on the integrity of the blood-brain barrier in vitro" 64 (64): 37-43, 1996

16 May J. Reed, "The extracellular matrix of the blood–brain barrier: structural and functional roles in health, aging, and Alzheimer’s disease" Informa UK Limited 7 (7): 1651157-, 2019

17 Marchi N, "The etiological role of blood-brain barrier dysfunction in seizure disorders" 2011

18 Zlokovic BV, "The blood-brain barrier in health and chronic neurodegenerative disorders" 57 (57): 178-201, 2008

19 Kim SY, "TGFβ signaling is associated with changes in infl ammatory gene expression and perineuronal net degradation around inhibitory neurons following various neurological insults" 7 (7): 1-14, 2017

20 Ivens S, "TGF-β receptormediated albumin uptake into astrocytes is involved in neocortical epileptogenesis" 130 (130): 535-547, 2007

21 Ostrow LW, "Stretch-induced endothelin-1 production by astrocytes" 36 (36): :S274-–S277, 2000

22 Nitta T, "Size-selective loosening of the blood-brain barrier in claudin-5–defi cient mice" 161 (161): 653-660, 2003

23 Ferrer-Ferrer M, "Shaping synapses by the neural extracellular matrix" 12 : 40-, 2018

24 Alvarez XA, "Severity-related increase and cognitive correlates of serum VEGF levels in Alzheimer’s disease ApoE4 carriers" 63 (63): 1003-1013, 2018

25 Yamazaki Y, "Selective loss of cortical endothelial tight junction proteins during Alzheimer’s disease progression" 142 (142): 1077-1092, 2019

26 Librizzi L, "Seizureinduced brain-borne infl ammation sustains seizure recurrence and blood-brain barrier damage" 72 (72): 82-90, 2012

27 archi N, "Seizure-promoting eff ect of blood-brain barrier disruption" 48 (48): 732-742, 2007

28 Jin R, "Role of infl ammation and its mediators in acute ischemic stroke" 6 (6): 834-851, 2013

29 E.A. van Vliet, "Role of blood–brain barrier in temporal lobe epilepsy and pharmacoresistance" Elsevier BV 277 : 455-473, 2014

30 Kurshan PT, "Regulation of synaptic extracellular matrix composition is critical for proper synapse morphology" 34 (34): 2678-12689, 2014

31 Hubbard JA, "Regulation of astrocyte glutamate transporter-1 (GLT1) and aquaporin-4 (AQP4) expression in a model of epilepsy" 283 : 85-96, 2016

32 Warth A, "Redistribution of aquaporin-4 in human glioblastoma correlates with loss of agrin immunoreactivity from brain capillary basal laminae" 4 : 311-318, 2004

33 Milesi S, "Redistribution of PDGFRβ cells and NG2DsRed pericytes at the cerebrovasculature after status epilepticus" 71 : 151-115, 2014

34 Sung JY, "Proteolytic cleavage of extracellular secreted α-synuclein via matrix metalloproteinases" 280 (280): 25216-25224, 2005

35 Toni S. Pearson, "Phenotypic Spectrum of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)" Springer Science and Business Media LLC 13 (13): 342-, 2013

36 ulik A, "Pericytes regulate the blood-brain barrier" 468 (468): 557-561, 2010

37 Sweeney MD, "Pericytes of the neurovascular unit: key functions and signaling pathways" 19 (19): 771-783, 2016

38 Olson LE, "PDGFRβ signaling regulates mural cell plasticity and inhibits fat development" 20 (20): 815-826, 2011

39 Gwen McCaffrey, "P-glycoprotein trafficking at the blood-brain barrier altered by peripheral inflammatory hyperalgesia" Wiley 122 (122): 962-975, 2012

40 Zhao X, "Noninfl ammatory changes of microglia are suffi cient to cause epilepsy" 22 (22): 2080-2093, 2018

41 Dipan C. Patel, "Neuron–glia interactions in the pathophysiology of epilepsy" Springer Science and Business Media LLC 20 (20): 282-297, 2019

42 Carrano A, "Neuroinfl ammation and blood-brain barrier changes in capillary amyloid angiopathy" 10 (10): 329-331, 2012

43 Khaled H. Elfakhri, "Multi-faceted therapeutic strategy for treatment of Alzheimer's disease by concurrent administration of etodolac and α-tocopherol" Elsevier BV 125 : 123-134, 2019

44 Chaturvedi M, "Mmp-9 inhibition: a therapeutic strategy in ischemic stroke" 49 (49): 563-573, 2014

45 Eyo UB, "Microglia–neuron communication in epilepsy" 65 (65): 5-18, 2017

46 Voet S, "Microglia in central nervous system infl ammation and multiple sclerosis pathology" 25 (25): 112-123, 2019

47 White AR, "Metal homeostasis in Alzheimer’s disease" 6 (6): 711-722, 2006

48 Glass CK, "Mechanisms underlying inflammation in neurodegeneration" 140 (140): 918-934, 10

49 Roisin McMackin, "Measuring network disruption in neurodegenerative diseases: New approaches using signal analysis" BMJ 90 (90): 1011-1020, 2019

50 Maryam G. Rohani, "Matrix remodeling by MMPs during wound repair" Elsevier BV 44-46 : 113-121, 2015

51 Chandler S, "Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview" 72 (72): 155-161, 1997

52 Mizoguchi H, "Matrix metalloproteinase-9 contributes to kindled seizure development in pentylenetetrazole-treated mice by converting proBDNF to mature BDNF in the hippocampus" 31 (31): 12963-12971, 2011

53 Ralf G. Rempe, "Matrix Metalloproteinase-Mediated Blood-Brain Barrier Dysfunction in Epilepsy" Society for Neuroscience 38 (38): 4301-4315, 2018

54 Saran Feng, "Matrix Metalloproteinase-2 and -9 Secreted by Leukemic Cells Increase the Permeability of Blood-Brain Barrier by Disrupting Tight Junction Proteins" Public Library of Science (PLoS) 6 (6): e20599-, 2011

55 Bar-Klein G, "Losartan prevents acquired epilepsy via TGF-β signaling suppression" 75 (75): 864-887, 2014

56 Yong Ping, "Linking Aβ42-Induced Hyperexcitability to Neurodegeneration, Learning and Motor Deficits, and a Shorter Lifespan in an Alzheimer’s Model" Public Library of Science (PLoS) 11 (11): e1005025-, 2015

57 Seiff ert E, "Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex" 24 (24): 7829-7836, 2004

58 Hofer S, "Injury of the blood brain barrier and up-regulation of icam-1 in polymicrobial sepsis" 146 (146): 276-281, 2008

59 Amor S, "Infl ammation in neurodegenerative diseases–an update" 142 (142): 151-166, 2014

60 Akiyama H, "Infl ammation and Alzheimer’s disease" 21 (21): 383-421, 2000

61 Castañeda-Cabral JL, "Increased protein expression of VEGF-A, VEGF-B, VEGF-C and their receptors in the temporal neocortex of pharmacoresistant temporal lobe epilepsy patients" 328 : 68-72, 2019

62 Justin A. McClain, "Increased MMP-3 and CTGF expression during lipopolysaccharide-induced dopaminergic neurodegeneration" Elsevier BV 460 (460): 27-31, 2009

63 Bhowmick S, "Impairment of pericyte-endothelium crosstalk leads to blood-brain barrier dysfunction following traumatic brain injury" 317 : 260-270, 2019

64 Sternlicht MD, "How matrix metalloproteinases regulate cell behavior" 17 (17): 463-516, 2001

65 Vazana U, "Glutamate-mediated blood-brain barrier opening: implications for neuroprotection and drug delivery." 36 (36): 7727-7739, 2016

66 Hildebrand MS, "Glucose metabolism transporters and epilepsy: only GLUT 1 has an established role" 55 (55): e18-e21, 2014

67 Gupta RK, "Glial molecular alterations with mouse brain development and aging: up-regulation of the Kir4. 1 and aquaporin-4" 35 (35): 59-67, 2013

68 Corder EH, "Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families" 261 (261): 921-923, 1993

69 Winkler EA, "GLUT1 reductions exacerbate Alzheimer’s diseasevasculo-neuronal dysfunction and degeneration" 521-530, 2015

70 Yoshihiro Murata, "Extension of the Thrombolytic Time Window With Minocycline in Experimental Stroke" Ovid Technologies (Wolters Kluwer Health) 39 (39): 3372-3377, 2008

71 Castañeda-Cabral JL, "Expression of VEGF-and tight junction-related proteins in the neocortical microvasculature of patients with drug-resistant temporal lobe epilepsy" 132 : 104059-, 2020

72 Zhao Z, "Establishment and dysfunction of the blood-brain barrier" 163 (163): 1064-1078, 2015

73 García-González L, "Emerging alternative proteinases in APP metabolism and Alzheimer’s disease pathogenesis: a focus on MT1-MMP and MT5-MMP" 11 : 244-, 2019

74 Barbara Pijet, "Elevation of MMP-9 Levels Promotes Epileptogenesis After Traumatic Brain Injury" Springer Science and Business Media LLC 55 (55): 9294-9306, 2018

75 Lee P, "Eff ects of aging on blood brain barrier and matrix metalloproteases following controlled cortical impact in mice" 234 (234): 50-61, 2012

76 Kim J, "ETB receptor-mediated MMP-9 activation induces vasogenic edema via ZO-1 protein degradation following status epilepticus" 304 : 355-367, 2015

77 Gorter JA, "Dynamic changes of proteases and protease inhibitors revealed by microarray analysis in CA3 and entorhinal cortex during epileptogenesis in the rat" 48 : 53-64, 2007

78 Sebastian Poliak, "Distinct claudins and associated PDZ proteins form different autotypic tight junctions in myelinating Schwann cells" Rockefeller University Press 159 (159): 361-372, 2002

79 Li Y-J, "Disruption of the blood-brain barrier after generalized tonic-clonic seizures correlates with cerebrospinal fl uid MMP-9 levels" 10 (10): 1-9, 2013

80 Nakazato R, "Disruption of Bmal1 impairs blood-brain barrier integrity via pericyte dysfunction" 37 (37): 10052-10062, 2017

81 Nathalie A. Py, "Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of Alzheimer’s disease: evidence for a pro-amyloidogenic role of MT1-MMP" Frontiers Media SA 6 : 247-, 2014

82 Miners JS, "Diff ering associations between Aβ accumulation, hypoperfusion, blood-brain barrier dysfunction and loss of PDGFRB pericyte marker in the precuneus and parietal white matter in Alzheimer’s disease" 38 (38): 103-115, 2018

83 Svetlana M. Stamatovic, "Decline in Sirtuin-1 expression and activity plays a critical role in blood-brain barrier permeability in aging" Elsevier BV 126 : 105-116, 2019

84 Günzel D, "Claudins and the modulation of tight junction permeability" 93 (93): 525-569, 2013

85 Ongnok B, "Chattipakorn SC (2021) Donepezil provides neuroprotective eff ects against brain injury and Alzheimer’s pathology under conditions of cardiac ischemia/reperfusion injury" 1 : 165975-, 1867

86 Yan BC, "Changes in the blood-brain barrier function are associated with hippocampal neuron death in a kainic acid mouse model of epilepsy" 9 : 775-, 2018

87 Winkler EA, "Central nervous system pericytes in health and disease" 14 (14): 1398-, 2011

88 Araque A, "Calcium elevation in astrocytes causes an NMDA receptor-dependent increase in the frequency of miniature synaptic currents in cultured hippocampal neurons" 18 (18): 6822-6829, 1998

89 Gordon GR, "Brain metabolism dictates the polarity of astrocyte control over arterioles" 456 (456): 745-749, 2008

90 Vezzani A, "Brain infl ammation in epilepsy: experimental and clinical evidence" 46 (46): 1724-1743, 2005

91 Mahoney ER, "Brain expression of the vascular endothelial growth factor gene family in cognitive aging and Alzheimer’s disease" 2019

92 Roshini Prakash, "Blood−brain barrier breakdown and neovascularization processes after stroke and traumatic brain injury" Ovid Technologies (Wolters Kluwer Health) 28 (28): 556-564, 2015

93 Dhanda S, "Blood-brain barrier permeability is exacerbated in experimental model of hepatic encephalopathy via MMP-9 activation and downregulation of tight junction proteins" 55 (55): 3642-3659, 2018

94 Van Vliet E, "Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy" 130 (130): 521-534, 2007

95 Heinemann U, "Blood-brain barrier dysfunction, TGFβ signaling, and astrocyte dysfunction in epilepsy" 60 (60): 1251-1257, 2012

96 Kortekaas R, "Blood-brain barrier dysfunction in parkinsonian midbrain in vivo" 57 (57): 176-179, 2005

97 Senatorov VV, "Blood-brain barrier dysfunction in aging induces hyperactivation of TGFβ signaling and chronic yet reversible neural dysfunction" 2019

98 Elahy M, "Blood-brain barrier dysfunction developed during normal aging is associated with infl ammation and loss of tight junctions but not with leukocyte recruitment" 12 (12): 1-9, 2015

99 Seda Salar, "Blood-brain barrier dysfunction can contribute to pharmacoresistance of seizures" Wiley 55 (55): 1255-1263, 2014

100 Bowman GL, "Blood-brain barrier breakdown, neuroinfl ammation, and cognitive decline in older adults" 12 : 1640-1650, 2018

101 Nation DA, "Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction" 25 (25): 270-276, 2019

102 Montagne A, "Blood-brain barrier breakdown in the aging human hippocampus" 85 (85): 296-302, 2015

103 Kim SH, "Beyond symptomatic eff ects: potential of donepezil as a neuroprotective agent and disease modifi er in Alzheimer’s disease" 174 (174): 4224-4232, 2017

104 Abbott NJ, "Astrocyte–endothelial interactions and blood–brain barrier permeability" 200 (200): 523-534, 2002

105 Zeppenfeld DM, "Association of perivascular localization of aquaporin-4 with cognition and Alzheimer disease in aging brains" 74 (74): 91-99, 2017

106 José Rafael Romero, "Association of matrix metalloproteinases with MRI indices of brain ischemia and aging" Elsevier BV 31 (31): 2128-2135, 2010

107 ALLEN D. ROSES, "Apolipoprotein E and ALzheimer's Disease: The Tip of the Susceptibility Iceberg" Wiley 855 (855): 738-743, 1998

108 Chen Y-C, "Anterior thalamic nuclei deep brain stimulation reduces disruption of the blood-brain barrier, albumin extravasation, infl ammation and apoptosis in kainic acid-induced epileptic rats" 39 (39): 1103-1113, 2017

109 Biron KE, "Amyloid triggers extensive cerebral angiogenesis Gusing blood brain barrier permeability and hypervascularity in Alzheimer’s disease" 6 (6): e23789-, 2011

110 Hooijmans CR, "Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice" 1181 : 93-103, 2007

111 Barber AJ, "Agrin accumulates in the brain microvascular basal lamina during development of the blood-brain barrier" 208 (208): 62-74, 1997

112 Goodall EF, "Age‐associated changes in the blood‐brain barrier: comparative studies in human and mouse" 3 : 328-334, 2018

113 Hou Y, "Ageing as a risk factor for neurodegenerative disease" 15 (15): 565-581, 2019

114 Kooij G, "Adenosine triphosphate-binding cassette transporters mediate chemokine (CC motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis" 134 (134): 555-570, 2011

115 Lazarevich I, "Activity-dependent switches between dynamic regimes of extracellular matrix expression" 15 (15): e0227917-, 2020

116 Shigemoto-Mogami Y, "Activated microglia disrupt the blood-brain barrier and induce chemokines and cytokines in a rat in vitro model" 12 : 494-, 2018

117 Halliday MR, "Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease" 36 (36): 216-227, 2016

118 KOEN PAEMELEIRE, "ATP-Dependent Astrocyte-Endothelial Calcium Signaling Following Mechanical Damage to a Single Astrocyte in Astrocyte-Endothelial Co-Cultures" Mary Ann Liebert Inc 17 (17): 345-358, 2000

119 Montagne A, "APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline" 581 (581): 71-76, 2020

120 Kim YS, "A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation" 21 (21): 179-187, 2007

121 Choi DH, "A novel intracellular role of matrix metalloproteinase‐3 during apoptosis of dopaminergic cells" 06 (06): 405-415, 2008

122 Elahi FM, "A clinicopathological approach to the diagnosis of dementia" 8 : 457-, 2017